Apricus Biosciences (APRI) +12.5% premarket after announcing it has licensed Takeda...

Apricus Biosciences (APRI) +12.5% premarket after announcing it has licensed Takeda Pharmaceuticals (TKPHF.PK, TKPYY.PK) to market Vitaros, its erectile dysfunction drug, in the U.K. Takeda will pay APRI an undisclosed upfront payment and milestone payments of up to 35M euros.

Comments (1)
  • Clariske
    , contributor
    Comments (6) | Send Message
    Vitaros will be launched this year. Apri have signed a big contract with Takeda and have contracts in different countries in Europe.
    After Viagra who was not so good for the liver, heart and eyes we are looking for the launch of Vitaros by Health Canada and the launch is for this year. It will be a blockbuster, no doubt about it . Every people will love and love is a reason for life. Enjoy Apri now , it is time to buy.
    14 Sep 2012, 04:00 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs